Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

TRPC6 G757D loss-of-function mutation associates with FSGS

  • Marc Riehle
  • , Anja K. Büscher
  • , Björn Oliver Gohlke
  • , Mario Kaßmann
  • , Maria Kolatsi-Joannou
  • , Jan H. Bräsen
  • , Mato Nagel
  • , Jan U. Becker
  • , Paul Winyard
  • , Peter F. Hoyer
  • , Robert Preissner
  • , Dietmar Krautwurst
  • , Maik Gollasch
  • , Stefanie Weber
  • , Christian Harteneck*
  • *Korrespondierende/r Autor/-in für diese Arbeit
  • Eberhard Karls Universität Tübingen
  • Universität Duisburg-Essen
  • Deutsches Krebsforschungszentrum
  • Charité – Universitätsmedizin Berlin
  • UCL Great Ormond Street Institute of Child Health
  • Medizinische Hochschule Hannover
  • Center of Nephrology and Metabolic Disorders
  • Universitätsklinikum Köln

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

109 Zitate (Scopus)

Abstract

FSGS is a CKD with heavy proteinuria that eventually progresses to ESRD. Hereditary forms of FSGS have been linked to mutations in the transient receptor potential cation channel, subfamily C, member 6 (TRPC6) gene encoding a nonselective cation channel. Most of these TRPC6 mutations cause a gain-of-function phenotype, leading to calcium-triggered podocyte cell death, but the underlying molecular mechanisms are unclear. We studied the molecular effect of disease-related mutations using tridimensional in silico modeling of tetrameric TRPC6. Our results indicated that G757 is localized in a domain forming a TRPC6-TRPC6 interface and predicted that the amino acid exchange G757D causes local steric hindrance and disruption of the channel complex. Notably, functional characterization of model interface domain mutants suggested a loss-of-function phenotype. We then characterized 19 human FSGS-related TRPC6 mutations, the majority of which caused gain-of-function mutations. However, five mutations (N125S, L395A, G757D, L780P, and R895L) caused a loss-of-function phenotype. Coexpression of wild-type TRPC6 and TRPC6 G757D, mimicking heterozygosity observed in patients, revealed a dominant negative effect of TRPC6 G757D. Our comprehensive analysis of human disease-causing TRPC6 mutations reveals loss of TRPC6 function as an additional concept of hereditary FSGS and provides molecular insights into the mechanismresponsible for theloss-of-functionphenotypeof TRPC6G757Din humans.

OriginalspracheEnglisch
Seiten (von - bis)2771-2783
Seitenumfang13
FachzeitschriftJournal of the American Society of Nephrology
Jahrgang27
Ausgabenummer9
DOIs
PublikationsstatusVeröffentlicht - 2016

Fingerprint

Untersuchen Sie die Forschungsthemen von „TRPC6 G757D loss-of-function mutation associates with FSGS“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren